Get Premium to unlock powerful stock data
Y-mAbs Therapeutics Inc logo

Y-mAbs Therapeutics Inc

$ 10.71 +0.38 (+3.68%) 04:00 PM EST
P/E:
At Loss
P/B:
2.91
Market Cap:
$ 468.22M
Enterprise V:
$ 297.93M
Volume:
300.33K
Avg Vol (2M):
445.55K
Volume:
300.33K
Market Cap $:
468.22M
PE Ratio:
At Loss
Avg Vol (2-Month):
445.55K
Enterprise Value $:
297.93M
PB Ratio:
2.91
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Y-mAbs Therapeutics Inc
NAICS : 325412 SIC : 2834
230 Park Avenue, Suite 3350, New York, NY, USA, 10169
Description
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Its pipeline covers Naxitamab, Omburtamab, GD2-GD3 Vaccine, and others.
Name Current Vs Industry Vs History
Cash-To-Debt 51.4
Equity-to-Asset 0.82
Debt-to-Equity 0.02
Debt-to-EBITDA -0.03
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.53
Distress
Grey
Safe
Beneish M-Score -2.36
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 57.79
9-Day RSI 53.75
14-Day RSI 51.2
6-1 Month Momentum % -38.3
12-1 Month Momentum % -69.35

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.12
Quick Ratio 5.93
Cash Ratio 5.4
Days Inventory 355.59
Days Sales Outstanding 70.84
Days Payable 902.77

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.5

Financials (Next Earnings Date:2022-08-05 Est.)

YMAB's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:YMAB

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 40
EPS (TTM) ($) -2.68
Beta 1.42
Volatility % 67.82
14-Day RSI 51.2
14-Day ATR ($) 1.011278
20-Day SMA ($) 9.456
12-1 Month Momentum % -69.35
52-Week Range ($) 6.5 - 39.8199
Shares Outstanding (Mil) 43.72

Piotroski F-Score Details

Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Y-mAbs Therapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More